Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therap...
Merck's KEYNOTE-B96 trial shows Keytruda with chemotherapy improves survival in platinum-resistant recurrent ovarian cancer...
Significant progress in bulk RNA sequencing, methylation mapping, multiomics integration, and spatial analyses unlocks research...
Roche, in collaboration with KlinRisk, Inc, has received CE-mark for the first AI-based risk stratification tool for assessment...
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study...
Roche ((SIX: RO, ROG, OTCQX:RHHBY) announced today that it has commenced a tender offer for all of the outstanding shares of co...
Recently granted CE Mark, the novel test delivers improved sensitivity and accuracy for faster and more reliable diagnosis in e...
